




































































































































Manuscript ID number: 
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Title of paper: 
Knowledge, attitudes, practices and information needs during the COVID-19 pandemic in Indonesia
Reviewer 1
Evaluations (peer review comments for the author)
1. In general, how do you rate the degree to which the paper is easy to follow and its logical flow?
 
Fair
2. Do the title and abstract cover the main aspects of the work?
 
No. Remdisvir is approved for COVID-19. Kindly make your background information on why KAP is important Indonesia is not
having COVID-19 cases.
Kindly structure your abstract the present abstract is junky and was not clear methodology. Snowball sampling is not good
for cross-sectional studies and why authors selected 819 samples to answer the study objective was not clear. What are the
factors, %, mean values, OR, 95% CI? 
The abstract is highly descriptive.
3. If relevant are the results novel? Does the study provide an advance in the field?
 
No. Nothing novel and not added any new information to the field.
4. Did the study gain ethical approval appropriate to the country in which the research was performed if human or
animal subjects, human cell lines or human tissues were involved and is it stated in the manuscript?
 
Yes
Does the paper raise any ethical concerns?
 
Yes. But authors did not specify the Informed consent and other patient concerns information in the manuscript.
5. If relevant, are the methods clear and replicable?
 
No. Methodological issues, not validated the questionnaire, not properly described the study sample, and several pitfalls.
6. If relevant, do all the results presented match the methods described?
 
No. Too many tables and figures. Almost distracting
7. If relevant, is the statistical analysis appropriate to the research question and study design?
 
No. I dont understand why authors are applying all analysis without a proper study objective.
8. If relevant, is the selection of the controls appropriate for the study design. Have attempts been made to address
potential bias through analytic methods, eg., sensitivity analysis
 
No. Not clear methods and not able to clarify the sensitivity of the test
9. How do you rate how clearly and appropriately the data are presented
 
Fair. Not so good and not suitable for high impact journals
10. If relevant, did the authors, make the underlying data available to the readers?
 
No. This is a cross-sectional study, there is no use of making data available to readers
11. Do the conclusions correlate to the results found?
 
No. The authors are stating something that is not related to their study objective
12. Are the figures and tables clear and legible?
 
No. Too many
Are images clear and free from unnecessary modification?
 
Yes
13. I have serious concerns about the validity of this manuscript
 
No. but parts of the manuscript where information is provided without proper references
14. Does the paper use appropriate references in the correct style to promote understanding of the content?
 
No. Not reviewed the right papers to use for this study.
15. If relevant, do any of the authors competing interests raise concerns about the validity of the study i.e. have the
authors' competing interests created a bias in the reporting of the results and conclusions?.
 
NA





The manuscript requires significant revision and not truly novel. There are several pitfalls and ambiguous sentences that are
irrelevant to the aim and objectives of the study. 
Remdisvir is approved for COVID-19. Kindly make your background information on why KAP is important Indonesia is not
having COVID-19 cases.
Kindly structure your abstract the present abstract is junky and was not clear methodology. Snowball sampling is not good
for cross-sectional studies and why authors selected 819 samples to answer the study objective was not clear. What are the
factors, %, mean values, OR, 95% CI?
Reviewer 2
Evaluations (peer review comments for the author)
1. In general, how do you rate the degree to which the paper is easy to follow and its logical flow?
 
Good
2. Do the title and abstract cover the main aspects of the work?
 
Yes
3. If relevant are the results novel? Does the study provide an advance in the field?
 
Yes. Novel for a country like that being investigated.
4. Did the study gain ethical approval appropriate to the country in which the research was performed if human or
animal subjects, human cell lines or human tissues were involved and is it stated in the manuscript?
 
Yes
Does the paper raise any ethical concerns?
 
Yes. Yes; collecting names and stating that google froms were reviewed by contacting the participants indicate that identifiers
were collected. This is a concern as online surveys should not collect such and participants should not be easily traced and
contacted.
5. If relevant, are the methods clear and replicable?
 
Yes. Details about the questions for each of the KAP domains should be stated in the instrument section. Coding of the
responses as well should be clearly stated. The choice of statistical tests should be clearly explained. Why non-parametric
tests used.
6. If relevant, do all the results presented match the methods described?
 
Yes
7. If relevant, is the statistical analysis appropriate to the research question and study design?
 
Yes. See note in section 5.
8. If relevant, is the selection of the controls appropriate for the study design. Have attempts been made to address
potential bias through analytic methods, eg., sensitivity analysis
 
NA
9. How do you rate how clearly and appropriately the data are presented
 
Excellent
10. If relevant, did the authors, make the underlying data available to the readers?
 
Yes
11. Do the conclusions correlate to the results found?
 
Yes. Conclusion could be further shortened to include only a sentence or two that are related to the results without any extra
statements.
12. Are the figures and tables clear and legible?
 
Yes
Are images clear and free from unnecessary modification?
 
Yes
13. I have serious concerns about the validity of this manuscript
 
Yes. Multiple variables could be collapsed into less categories to better reflect on statistical testing. Marital status, for
example, could be collapsed into Never married and ever married. This will increase the power of comparison as the
numbers within each cell will increase. 
Age and education could be confounded and this is a limitation that should be stated. 
70% females is a clear introduction bias that limits generalizability. 
Authors should discuss how socio-demographics of the sample reflect on the reference population.
14. Does the paper use appropriate references in the correct style to promote understanding of the content?
 
Yes
15. If relevant, do any of the authors competing interests raise concerns about the validity of the study i.e. have the
authors' competing interests created a bias in the reporting of the results and conclusions?.
 
No





Paper is well written but can be fine tunes to correct some English editing. Objectives are clear and very well presented in the
results. 
In the introduction: Non-Pharmacutical Intervention measures have a major role in mitigating the risk of COVID-19. No where
does the paper present this term(s). Also, NPI measures have been successful in mitigating the risk; but data may not be
available from the country under investigation.
 I suggest editing this part t include these comments, especially when stating that" The effectiveness of these interventions is
not known". 
"In this case, KAP is essential for health authorities on developing COVID-19 prevention measures in the community."
developing here is better changed into adjusted and fine tuned. 
In the objective; please use "information needs and seeking behaviors". 
Study design:
How the signed consent form was signed and returned? Not sure this is feasible in google forms. 
This sentense is better deleted as it is confusing: "This age group was categorised as teenagers, according to the Indonesian
Ministry of Health".
Instruments:
Details on questions used for each of the 4 main domains are needed. What answer options were available; was it a Likert
scale? Yes/no? 
Any statistics about reliability? 
WHy were names collected? Was this approved by IRB? 
How was this feasible in google forms: "To maintain the participant validity, we limited each account to only one response. At
the end of the survey, the link was collapsed, and the data downloaded for data completeness. If there was any vague
answer, we clarified the response with the participant via WhatsApp or telephone."
Stat analysis: the maximum score: What is the maximum total? How was it calculated? 
WHy were the Mann-Whitney U and Kruskal Wallis tests selected?  This section needs clear clarifications of what was
compared. 
Results:
Socio-characteristics: valid is better changed to eligible and said to reported. 
Marital status, occupation, and education are better collared into less categories to be able to properly compare. FOr
example, MSc and PhD could be combined together, marries and divorced into ever married. 
3.3 attitude
Indonesia might with the fight against. Change with to win. 
In tables, use one decimal point for the percentages. 
Limitations:
Sample design and having 70% females is a selection bias and limits generalizability. This is a major limitation. 
Suggestions for analysis: 
What will be the results of correlating knowledge to Attitudes and Precautionary measures? WIll higher knowledge transfer to
good precautionary measures?
Reviewer 3
Evaluations (peer review comments for the author)
1. In general, how do you rate the degree to which the paper is easy to follow and its logical flow?
 
Good
2. Do the title and abstract cover the main aspects of the work?
 
Yes
3. If relevant are the results novel? Does the study provide an advance in the field?
 
Yes
4. Did the study gain ethical approval appropriate to the country in which the research was performed if human or
animal subjects, human cell lines or human tissues were involved and is it stated in the manuscript?
 
Yes
Does the paper raise any ethical concerns?
 
No
5. If relevant, are the methods clear and replicable?
 
Yes
6. If relevant, do all the results presented match the methods described?
 
Yes
7. If relevant, is the statistical analysis appropriate to the research question and study design?
 
Yes
8. If relevant, is the selection of the controls appropriate for the study design. Have attempts been made to address
potential bias through analytic methods, eg., sensitivity analysis
 
Yes
9. How do you rate how clearly and appropriately the data are presented
 
Good
10. If relevant, did the authors, make the underlying data available to the readers?
 
No. Authors should provide a data availability statement.
11. Do the conclusions correlate to the results found?
 
Yes
12. Are the figures and tables clear and legible?
 
No. Graphs and images need to be produced at higher resolution
Are images clear and free from unnecessary modification?
 
Yes
13. I have serious concerns about the validity of this manuscript
 
No. Graphs need editing and higher resolutions.
14. Does the paper use appropriate references in the correct style to promote understanding of the content?
 
Yes
15. If relevant, do any of the authors competing interests raise concerns about the validity of the study i.e. have the
authors' competing interests created a bias in the reporting of the results and conclusions?.
 
No





Methods: Provide equations/methods for sample size determination.
Results: add frequency before each percentage. On each percentage add the 95% CI for each.
I also think you used minitab, if so, is it possible to find another software to improve the quality of the images/graphs?
Fig 3 is difficult to read. Can you redraw and present an editable version or attach it as a supplementary file to the editorial
office?
Reviewer 4
Evaluations (peer review comments for the author)
1. In general, how do you rate the degree to which the paper is easy to follow and its logical flow?
 
Good
2. Do the title and abstract cover the main aspects of the work?
 
Yes
3. If relevant are the results novel? Does the study provide an advance in the field?
 
No. This area of research was studied in different countries before.
4. Did the study gain ethical approval appropriate to the country in which the research was performed if human or
animal subjects, human cell lines or human tissues were involved and is it stated in the manuscript?
 
Yes
Does the paper raise any ethical concerns?
 
No
5. If relevant, are the methods clear and replicable?
 
Yes
6. If relevant, do all the results presented match the methods described?
 
Yes
7. If relevant, is the statistical analysis appropriate to the research question and study design?
 
Yes
8. If relevant, is the selection of the controls appropriate for the study design. Have attempts been made to address
potential bias through analytic methods, eg., sensitivity analysis
 
NA
9. How do you rate how clearly and appropriately the data are presented
 
Excellent
10. If relevant, did the authors, make the underlying data available to the readers?
 
Yes
11. Do the conclusions correlate to the results found?
 
Yes
12. Are the figures and tables clear and legible?
 
Yes
Are images clear and free from unnecessary modification?
 
Yes
13. I have serious concerns about the validity of this manuscript
 
No
14. Does the paper use appropriate references in the correct style to promote understanding of the content?
 
Yes
15. If relevant, do any of the authors competing interests raise concerns about the validity of the study i.e. have the
authors' competing interests created a bias in the reporting of the results and conclusions?.
 
No





1- I would rather if the authors conduct regression analysis to identify the association between demographics and knowledge
and practice score.
2- line 25, the statement "have a positive attitude, but they provided an inadequate response to government policies" is
contradictory.
3- line 108, It is not mentioned how the authors employed the snowball sampling technique.
4- line 125, Chi-squared test is not used to analyse association but to see if there is a statistically significant difference
between groups.
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